Neuropeptide Y
What the Research Actually Shows
Human: 2 studies, 4 groups · Animal: 1 · In Vitro: 0
The resilience peptide that Special Forces soldiers produce under extreme stress—with Phase Ib clinical data for PTSD, a 36-amino-acid delivery problem, and three decades of promise without a single approved therapy
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Your body makes neuropeptide Y when you are under stress. People who handle extreme stress well—including Special Forces soldiers—tend to make more of it. People with PTSD tend to have less of it in their spinal fluid. Researchers tested NPY as a nasal spray in PTSD patients in a Phase Ib trial, and the high dose reduced anxiety. A separate small trial tested it in depression. Neither led to an approved drug. NPY is a large molecule—36 amino acids—and getting enough of it from the nose to the brain remains a real pharmacological challenge. The biology is strong, the clinical path is early.
Neuropeptide Y is one of the most abundant signaling molecules in the human brain. It regulates appetite, circadian rhythms, cardiovascular function, and—most relevant to this cluster—the stress response. NPY acts as a physiological counterweight to corticotropin-releasing hormone (CRH, also in Cluster J): where CRH activates the stress axis, NPY dampens it.
The clinical interest in NPY centers on a striking observation: resilience to extreme stress correlates with NPY levels. Studies of military personnel in survival training found that soldiers who maintained higher plasma NPY concentrations during interrogation stress recovered faster and showed fewer PTSD symptoms. Conversely, PTSD patients show significantly lower NPY concentrations in their cerebrospinal fluid compared to healthy controls (Sah et al., 2009; PMID 19576571).
This led to the logical question: can exogenous NPY treat stress disorders? A Phase Ib trial (Sayed et al., 2018; PMID 29016993) tested intranasal NPY in PTSD patients and found dose-dependent anxiety reduction with no serious adverse events. A second RCT tested intranasal NPY in major depressive disorder (Mathé et al., 2020; PMID 33049051). Both studies were small, early-stage, and exploratory—and neither has led to a therapeutic product. This article examines why the biology is so compelling, what the clinical data actually shows, and what stands between NPY and a viable treatment.
In This Article
Quick Facts: Neuropeptide Y at a Glance
Type
Endogenous neuropeptide, 36 amino acids, pancreatic polypeptide family
Also Known As
NPY, Neuropeptide Tyrosine
Generic Name
Neuropeptide Y (no pharmaceutical generic name—no approved product exists)
Route
Intranasal (clinical trials). IV infusion (research). No subcutaneous protocol established. Intranasal delivery exploits olfactory/trigeminal pathways to bypass the blood-brain barrier, but CNS bioavailability remains uncharacterized.
Molecular Weight
~4,272 Da
Peptide Sequence
36-amino-acid linear peptide with C-terminal amidation (Tyr-Pro-Ser-Lys...Tyr-NH₂); member of the NPY/PYY/PP family sharing the PP-fold tertiary structure
Endogenous Origin
Yes. One of the most abundant neuropeptides in the mammalian CNS—widely expressed in hypothalamus, amygdala, locus coeruleus, cerebral cortex, and sympathetic nervous system
Primary Molecular Function
Binds five receptor subtypes (Y1, Y2, Y4, Y5, Y6). Y1 activation in the amygdala mediates anxiolysis. Y2 is a presynaptic autoreceptor (anxiogenic when activated). Y5 mediates appetite stimulation. Differential receptor activation produces opposing effects.
Active Fragment
Full-length NPY (1–36) is the primary active form. NPY 3–36 (DPP-IV cleavage product) preferentially activates Y2/Y5 over Y1. C-terminal fragments (13–36, 18–36) retain Y2 selectivity.
Brand Name
None. No FDA-approved NPY therapeutic exists for any indication.
Related Compound Relationship
Peptide YY (PYY) shares 70% sequence homology—PYY 3–36 is the satiety hormone. Pancreatic polypeptide (PP) is the third family member. CRH (also in Cluster J) is NPY's physiological antagonist on the HPA axis.
Clinical Programs
Phase Ib: intranasal NPY for PTSD (Sayed et al., 2018). Phase 2: intranasal NPY for MDD (Mathé et al., 2020). No active IND filings for any NPY-based therapeutic as of 2025.
WADA Status
Not on the Prohibited List
Community Interest
Minimal. NPY is not widely available from consumer peptide vendors. The resilience-biomarker narrative generates interest in biohacking circles, but practical use is limited by delivery challenges and lack of established protocols.
FDA Status
Not approved for any indication. Not available as a pharmaceutical product. Research-grade NPY available from peptide suppliers.
Half-Life
Plasma: ~20–30 minutes (rapid DPP-IV cleavage to NPY 3–36). Brain half-life after intranasal delivery: unknown—no pharmacokinetic data published.
Evidence Tier
2 Clinical Trials
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Neuropeptide Y?
Pronunciation: NOOR-oh-PEP-tide why
Special Forces soldiers subjected to the most extreme stress training the military can devise—interrogation resistance, sleep deprivation, caloric restriction, sustained physical exertion—show wildly different biochemical responses. Some soldiers' blood chemistry spikes in all the expected stress markers and stays elevated. Others spike and recover rapidly. When researchers measured what distinguished the rapid recoverers, one molecule kept appearing: neuropeptide Y.
NPY is a 36-amino-acid peptide and one of the most abundant signaling molecules in the mammalian central nervous system. Discovered in 1982 by Karolinska Institute researchers Tatemoto and Mutt, it was named for the tyrosine residues at both its N- and C-termini (Y is the single-letter amino acid code for tyrosine). It belongs to the pancreatic polypeptide family alongside peptide YY (the satiety hormone) and pancreatic polypeptide, all sharing a distinctive hairpin-loop tertiary structure called the PP-fold.
PLAIN ENGLISH
Think of NPY as your brain's built-in stress buffer. When your stress response fires—cortisol rises, heart rate spikes, amygdala activates—NPY acts as the counterweight that brings everything back to baseline. People who make more of it recover from stress faster. People who make less of it are more vulnerable to conditions like PTSD. The research question is whether giving NPY from the outside can restore that buffering capacity.
Origins and Discovery
Kazuhiko Tatemoto isolated NPY from porcine brain extract in 1982 using a chemical assay for C-terminal amidation—the same technique that had led him to discover peptide YY the year before. The name was a structural descriptor: tyrosine (Y) at both the first and last positions. Within a decade, NPY had become one of the most intensely studied neuropeptides in neuroscience—not for any single function, but because it does so many things. It regulates feeding behavior, circadian rhythms, cardiovascular tone, body temperature, and, most provocatively, the stress response.
The military connection emerged in the early 2000s. Charles Morgan III and colleagues at Yale studied Special Forces trainees undergoing Survival, Evasion, Resistance, and Escape (SERE) training—a program designed to simulate prisoner-of-war conditions. Soldiers who showed superior stress resilience had significantly higher NPY levels both at baseline and during stress exposure, and their NPY levels recovered faster after stress cessation. This finding reframed NPY from a multifunctional neuropeptide to a potential molecular mechanism of psychological resilience.
PLAIN ENGLISH
NPY was discovered in pig brains in 1982 by a technique that detects a specific chemical modification. It turned out to be everywhere in the nervous system and involved in almost everything—eating, sleeping, blood pressure, stress. The military studies gave it a specific narrative: this might be what makes some people psychologically tougher under extreme conditions.
Mechanism of Action
The Y Receptor System
NPY's complexity arises from its receptor pharmacology. Five receptor subtypes (Y1 through Y6, with Y3 not confirmed in humans) mediate its effects, and critically, they can produce opposing outcomes:
Y1 receptor (anxiolytic axis): Y1 is expressed densely in the amygdala and hippocampus. Y1 activation inhibits GABAergic interneurons and modulates glutamatergic transmission, producing anxiolytic and anti-stress effects. This is the receptor responsible for NPY's resilience-promoting properties. Y1-knockout mice show increased anxiety and failure to develop fear extinction.
Y2 receptor (anxiogenic potential): Y2 functions as a presynaptic autoreceptor on NPY-releasing neurons—a negative feedback mechanism. Y2 activation reduces NPY release, which can paradoxically increase anxiety. Y2 antagonists are anxiolytic in rodent models. The clinical implication: full-length NPY (1–36) activates both Y1 and Y2, meaning the net anxiolytic effect depends on the balance of postsynaptic Y1 activation versus presynaptic Y2 autoinhibition.
Y5 receptor (appetite/sleep axis): Y5 mediates NPY's orexigenic (appetite-stimulating) effects and may contribute to sleep promotion. Y5 activation in the hypothalamus increases food intake and may influence sleep-wake transitions.
CRH Counterbalance
The most clinically relevant aspect of NPY's mechanism is its antagonism of corticotropin-releasing hormone. CRH (covered separately in this cluster) is the master activator of the stress response: it triggers ACTH release, cortisol production, and sympathetic arousal. NPY opposes CRH at multiple levels—reducing CRH expression in the hypothalamus, inhibiting CRH-induced ACTH release, and counteracting CRH's anxiogenic effects in the amygdala. In healthy stress physiology, NPY and CRH exist in dynamic balance. In PTSD, CSF NPY is low and CRH-driven stress responses are overactive.
Intranasal Delivery Rationale
NPY is a 4.2 kDa peptide that does not cross the blood-brain barrier in meaningful quantities after peripheral administration. The intranasal route exploits olfactory and trigeminal nerve pathways—direct anatomical connections between the nasal mucosa and the CNS—to deliver peptide to brain regions including the amygdala and hippocampus. This bypasses the BBB entirely, though the efficiency and consistency of this delivery route for a 36-amino-acid peptide remain uncharacterized.
PLAIN ENGLISH
NPY works through five different receptor types, and two of them have opposite effects on anxiety—Y1 calms you down, Y2 can ramp anxiety back up. The net effect depends on which receptor gets more activation. NPY also directly counteracts CRH, the hormone that drives your stress response. The nasal spray approach used in clinical trials tries to get NPY from the nose directly to the brain through nerve pathways, bypassing the blood-brain barrier that would otherwise block it.
Key Research Areas and Studies
The PTSD Intranasal Trial (Sayed et al., 2018)
Study: Phase Ib, double-blind, randomized, placebo-controlled, dose-ranging study of intranasal NPY in patients with PTSD. PMID: 29016993 Design: Approximately 30 PTSD patients randomized to multiple intranasal NPY dose levels versus placebo. Key findings: NPY was well tolerated at all tested doses. High-dose NPY showed dose-dependent reduction in anxiety measures. Plasma cortisol and ACTH responses to stress were attenuated. No serious adverse events. Limitations: Small sample size, single-dose administration (not repeated dosing), short follow-up, exploratory endpoints. Phase Ib is a safety/feasibility study—not powered for efficacy.
The Depression Trial (Mathé et al., 2020)
Study: Randomized controlled trial of intranasal NPY in major depressive disorder. PMID: 33049051 Design: ~24 patients with MDD received intranasal NPY or placebo. Key findings: Preliminary evidence for acute antidepressive efficacy. Rapid onset of mood improvement reported. Limitations: Small sample, single-center, exploratory. The "preliminary" framing in the authors' own abstract reflects the limitations they acknowledged.
The CSF Biomarker Study (Sah et al., 2009)
Study: Measurement of CSF neuropeptide Y concentrations in combat veterans with and without PTSD. PMID: 19576571 Design: Lumbar puncture–based CSF sampling in 28 combat veterans (PTSD vs. trauma-exposed controls vs. healthy controls). Key findings: PTSD patients had significantly lower CSF NPY concentrations than both control groups. CSF NPY correlated inversely with PTSD symptom severity. Significance: Establishes NPY as a biomarker of PTSD vulnerability, not just a correlate of acute stress response. This is the study that shifted the field from "NPY rises under stress" to "low NPY may be a risk factor for developing PTSD."
The Resilience Studies (Morgan et al., Military SERE Training)
Multiple publications from Charles Morgan III's group documented the NPY-resilience link: - Special Forces trainees showed higher baseline NPY and greater NPY release under stress - NPY levels predicted performance under interrogation stress - Post-stress NPY recovery was faster in resilient individuals These studies are primarily observational/correlational but collectively establish the strongest behavioral correlate of any single neuropeptide in stress resilience.
PLAIN ENGLISH
Two small clinical trials have tested NPY nasal spray—one in PTSD patients, one in depression patients. Both showed promising signals but were too small and early-stage to prove anything. A separate study found that PTSD patients have measurably lower levels of NPY in their spinal fluid. The military studies showed that soldiers who handle extreme stress best produce more NPY. Taken together, the biology makes a strong case. The clinical evidence is still thin.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “NPY reduces anxiety in PTSD patients” | Phase Ib trial showed dose-dependent anxiety reduction with intranasal NPY (Sayed et al., 2018, PMID 29016993). Single-dose, small sample, exploratory. | Mixed Evidence |
| “NPY is an antidepressant” | One small RCT showed preliminary antidepressive efficacy of intranasal NPY (Mathé et al., 2020, PMID 33049051). Not replicated. | Preclinical Only |
| “Low NPY causes PTSD” | CSF NPY is lower in PTSD patients (Sah et al., 2009, PMID 19576571), but correlation ≠ causation. Low NPY may be a risk factor, not a cause. | Mixed Evidence |
| “NPY nasal spray can treat anxiety disorders” | Intranasal delivery has shown feasibility in Phase Ib. No completed Phase 2 efficacy trial for any anxiety disorder. No approved product. | Preclinical Only |
| “Special Forces soldiers are resilient because of NPY” | Multiple observational studies correlate high NPY with stress resilience in military populations. Correlational—not proven causal. | Mixed Evidence |
| “NPY supplementation builds stress resilience” | No study has tested whether exogenous NPY supplementation improves stress resilience in healthy humans. Zero interventional data. | Unsupported |
| “NPY improves sleep” | NPY has hypnotic properties in animal models and antagonizes the sleep-disrupting effects of CRH. No human study has tested NPY for sleep improvement. | Preclinical Only |
| “NPY nasal spray is safe for self-use” | Phase Ib showed tolerability in a clinical setting with medical oversight. No safety data exists for self-administered intranasal NPY at uncontrolled doses. | Unsupported |
| “NPY reverses HPA axis dysfunction” | NPY antagonizes CRH and attenuates cortisol/ACTH responses in both animal models and the Phase Ib trial. Chronic effects on HPA axis in humans unknown. | Mixed Evidence |
| “NPY can be delivered effectively via nasal spray” | Phase Ib used intranasal delivery and showed CNS-mediated effects. Actual brain bioavailability of intranasal NPY-36 is uncharacterized. | Mixed Evidence |
| “NPY levels can be raised with lifestyle interventions” | Exercise increases peripheral NPY levels in some studies. Whether this translates to CNS NPY elevation or resilience benefits is unknown. | Mixed Evidence |
| “NPY is the key to understanding PTSD” | NPY is one of many systems dysregulated in PTSD (others: CRH, serotonin, norepinephrine, glutamate, endocannabinoids). Important but not singular. | Mixed Evidence |
The Human Evidence Landscape
The human evidence for NPY consists of two small clinical trials and a handful of biomarker and observational studies. Neither trial has led to a therapeutic product, and no NPY-based drug is in late-stage clinical development.
Sayed et al., 2018 — Intranasal NPY in PTSD (PMID 29016993)
This Phase Ib study is the highest-quality clinical data for NPY. It used a proper randomized, double-blind, placebo-controlled design with dose escalation. Approximately 30 PTSD patients received intranasal NPY at multiple dose levels. The high dose reduced anxiety measures and attenuated plasma cortisol and ACTH. The study established safety and feasibility of intranasal delivery. However, it was explicitly designed as a safety and dose-finding study—not an efficacy trial. The sample was small, the intervention was a single dose, and follow-up was limited. No Phase 2 has followed in over six years.
Mathé et al., 2020 — Intranasal NPY in MDD (PMID 33049051)
This RCT tested intranasal NPY in approximately 24 patients with major depressive disorder. The authors reported "preliminary evidence for acute antidepressive efficacy." The study was small, single-center, and the authors themselves characterized their findings as preliminary. It has not been replicated.
Biomarker Studies
The Sah et al. (2009) study establishing low CSF NPY in PTSD is the most frequently cited human finding. It is a biomarker study—it measures a correlation, not a treatment effect. Multiple Morgan et al. studies of SERE trainees are observational. These studies collectively build a compelling biological narrative but do not constitute treatment evidence.
What Would Need to Happen
For NPY to advance as a therapy, a Phase 2a proof-of-concept trial with repeated dosing over weeks (not a single dose) in a PTSD population with validated outcome measures (CAPS-5) would need to demonstrate clinically meaningful symptom reduction. Additionally, brain bioavailability of intranasal NPY would need characterization—the clinical community cannot optimize dosing without knowing how much reaches the target. Neither study appears imminent.
PLAIN ENGLISH
Two small trials, promising signals, no follow-through. The PTSD trial was a safety study that happened to show reduced anxiety—but it was a single dose in about 30 people, and no one has run the larger efficacy trial that would tell us if it actually works as a treatment. The depression trial was similarly small and has not been repeated. The biomarker studies tell us NPY levels track with resilience and PTSD vulnerability, but that does not prove that giving NPY from the outside fixes the problem.
Safety, Risks, and Limitations
Tolerability in Clinical Trials
Intranasal NPY was well tolerated at all tested doses in the Phase Ib PTSD trial. No serious adverse events were reported. This is the extent of human safety data for exogenous NPY administration.
Theoretical Risks
Appetite stimulation: NPY is one of the most potent orexigenic signals in the brain, acting through Y1 and Y5 receptors in the hypothalamus. Chronic NPY administration could theoretically increase food intake and promote weight gain, though this has not been observed with intranasal dosing.
Cardiovascular effects: Peripheral NPY release from sympathetic nerve terminals causes vasoconstriction. NPY potentiates norepinephrine-induced vasoconstriction. Systemic NPY exposure could elevate blood pressure, particularly in individuals with pre-existing hypertension.
Y2-mediated anxiety: Because Y2 activation can increase anxiety (opposite of the desired Y1-mediated anxiolysis), the net effect of exogenous NPY depends on receptor occupancy patterns that may vary by dose, route, and individual receptor expression. The therapeutic window is theoretically narrow.
Immunomodulation: NPY modulates immune cell function—it can promote or suppress inflammatory responses depending on context. Long-term immunological consequences of repeated NPY administration are unknown.
Delivery Limitations
The 36-amino-acid size of NPY makes it too large for passive blood-brain barrier penetration. Intranasal delivery exploits direct nose-to-brain pathways but introduces variability: nasal mucosal condition, breathing technique, formulation, and device all affect how much peptide reaches the CNS. This is not a trivial technical challenge—it is the central reason NPY has not advanced beyond Phase Ib despite thirty years of compelling preclinical data.
PLAIN ENGLISH
NPY nasal spray was safe in the small trial that tested it. The bigger concerns are theoretical: it could increase appetite (NPY is a strong hunger signal), raise blood pressure (peripheral NPY constricts blood vessels), or produce unpredictable effects because its five receptor types include one that actually increases anxiety. The delivery problem—getting a large peptide from your nose to the right brain regions in consistent amounts—is probably the main reason no drug company has pushed this further.
Legal and Regulatory Status
NPY has no FDA-approved therapeutic indication. The synthetic peptide is available from research chemical suppliers but is not marketed as a pharmaceutical or dietary supplement. No IND is publicly listed for NPY-based therapeutics in the US. Intranasal NPY formulations used in clinical trials were investigator-prepared and not commercially available.
The diagnostic use of NPY as a PTSD biomarker (CSF NPY measurement) is a research tool, not an FDA-cleared diagnostic test. WADA does not list NPY on its Prohibited List.
Research Protocols and Formulation Considerations
Formulation
Clinical trials used lyophilized NPY reconstituted in saline for intranasal delivery via metered-dose nasal spray devices. Specific concentrations, excipients, and absorption enhancers used in the Sayed et al. trial were not fully described in the published report.
Storage
Research-grade NPY: lyophilized powder stored at −20°C (−4°F). Reconstituted solutions: 2–8°C (36–46°F), use within hours. NPY is susceptible to DPP-IV enzymatic degradation—the half-life in plasma is approximately 20–30 minutes due to rapid cleavage of the N-terminal Tyr-Pro dipeptide.
Stability
The C-terminal amidation of NPY improves stability relative to unmodified peptides but does not prevent enzymatic degradation. DPP-IV–resistant NPY analogs have been developed in preclinical research but have not been tested in humans.
Dosing in Published Research
The following table summarizes dosing protocols for Neuropeptide Y as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| Route | Intranasal (metered-dose nasal spray) |
| Dose range | Multiple dose levels tested; exact doses not publicly disclosed for all arms |
| High dose | Produced dose-dependent anxiety reduction in PTSD patients |
| Frequency | Single administration in Phase Ib (no repeated-dosing data) |
| Context | Phase Ib dose-ranging — safety and feasibility, not efficacy optimization |
| IV research dose | 50 pmol/kg/min infusion used in physiological studies (not therapeutic) |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Neuropeptide Y has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
NPY is not part of the mainstream peptide self-experimentation landscape. It is not widely stocked by consumer-facing peptide vendors, there is no established community dosing protocol, and intranasal delivery of a 36-amino-acid peptide requires specialized formulation beyond standard reconstitution practices. The few community discussions of NPY for stress or sleep are speculative and cite no dosing data from personal use.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Neuropeptide Y combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Neuropeptide Y with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Neuropeptide Y Compares
Neuropeptide Y belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is neuropeptide Y?
NPY is a 36-amino-acid peptide and one of the most abundant signaling molecules in your brain. It regulates appetite, stress responses, circadian rhythms, and cardiovascular function. It is endogenous—your body produces it naturally, especially in the hypothalamus, amygdala, and sympathetic nervous system.
Is NPY the same as peptide YY?
No. They are related—both belong to the pancreatic polypeptide family and share about 70% sequence similarity—but they have different distributions and functions. PYY (specifically PYY 3–36) is primarily a gut-derived satiety hormone. NPY is primarily a brain neuropeptide involved in stress, appetite, and sleep regulation.
Can NPY treat PTSD?
A Phase Ib trial showed that intranasal NPY reduced anxiety in PTSD patients at high doses, but this was a small safety study, not an efficacy trial. No Phase 2 trial has been completed, and no NPY-based therapeutic is in late-stage development for PTSD or any other condition.
Why do Special Forces soldiers have more NPY?
Multiple studies found that soldiers who show high resilience under extreme stress have higher baseline NPY levels and greater NPY release during stress. Whether this is cause (NPY produces resilience) or effect (resilient people happen to make more NPY) is not established. It may be both—a feedback loop where constitutionally higher NPY facilitates better stress coping, which in turn reinforces NPY system function.
Can I take NPY as a supplement?
Not in any practical sense. NPY is a 36-amino-acid peptide that does not survive oral digestion and does not cross the blood-brain barrier after injection. Clinical trials used specialized intranasal formulations—nasal sprays designed to deliver peptide directly to the brain via olfactory nerve pathways. There is no consumer product that replicates this.
Does exercise increase NPY levels?
Some studies show that intense exercise increases peripheral NPY levels. Whether peripheral increases translate to CNS NPY elevation is unclear—peripheral and central NPY pools are largely separate. Exercise has many documented benefits for stress resilience, but attributing those benefits specifically to NPY elevation is speculative.
How is NPY related to CRH?
NPY and CRH are physiological antagonists on the stress axis. CRH (corticotropin-releasing hormone, also covered in this cluster) activates the HPA stress response—it triggers cortisol release and sympathetic arousal. NPY counteracts CRH at multiple levels: it reduces CRH expression, inhibits CRH-induced ACTH release, and opposes CRH's anxiogenic effects in the amygdala. In healthy stress biology, they exist in dynamic balance. In PTSD, this balance is disrupted.
Is NPY safe?
Intranasal NPY was well tolerated in the Phase Ib trial with no serious adverse events. However, NPY has potent appetite-stimulating and cardiovascular effects, and the therapeutic window may be narrow because different NPY receptor subtypes can produce opposing effects (Y1 = calming, Y2 = potentially anxiety-increasing). No long-term safety data exists for exogenous NPY in humans.
Why hasn't NPY become a drug after 30 years of research?
Three main barriers. First, delivery—NPY is a large peptide that does not cross the blood-brain barrier, limiting administration to intranasal or intracerebroventricular routes. Second, receptor complexity—five receptor subtypes with different and sometimes opposing effects make it difficult to achieve a clean therapeutic effect. Third, economics—no pharmaceutical company has committed to the expensive clinical development program required, possibly because the patent landscape for a naturally occurring peptide is challenging.
Are there NPY-based drugs in development?
No NPY agonist is currently in late-stage clinical development. Research has explored NPY analogs with enhanced Y1 selectivity (to isolate the anxiolytic effect without Y2-mediated side effects), DPP-IV–resistant NPY variants (to extend the short half-life), and small-molecule Y1 agonists. None have advanced to Phase 2. The field has largely shifted toward understanding NPY genetics and epigenetics as biomarkers rather than pursuing the peptide itself as a therapeutic.
Can I raise my NPY naturally?
Evidence is limited but suggestive. Stress inoculation training (controlled exposure to moderate stressors) may upregulate NPY systems over time—this is one proposed mechanism for why military stress training builds resilience. Cold exposure, meditation, and exercise have all been loosely associated with NPY modulation in small studies, but none of these associations are established at a level that would support clinical recommendations.
Is NPY the same as the neuropeptide in \u0022neuropeptide therapy\u0022 products?
Usually no. Products marketed as \u0022neuropeptide therapy\u0022 (particularly in skincare) typically refer to other peptides—often copper peptides, acetyl hexapeptide, or proprietary sequences. These have no pharmacological relationship to NPY. The term \u0022neuropeptide\u0022 is used loosely in cosmetics marketing.
Summary of Key Findings
Neuropeptide Y represents one of the most compelling gaps between biological understanding and clinical application in the peptide field. The evidence that NPY is a central mediator of stress resilience is robust—from military studies of Special Forces personnel to CSF biomarker data in PTSD patients, the association between NPY and the ability to handle extreme stress is among the best-documented in neuropeptide research.
The translational challenge is equally clear. Two small clinical trials of intranasal NPY showed promising signals—anxiety reduction in PTSD, preliminary antidepressant effects—but neither was powered for efficacy, neither has been followed by larger trials, and neither has led to a therapeutic product. The pharmacological obstacles are significant: a 36-amino-acid peptide that does not cross the blood-brain barrier, five receptor subtypes with opposing effects, and a half-life measured in minutes. These are not problems that enthusiasm alone can solve.
For Peptidings readers, NPY is best understood as a biological explanation rather than a therapeutic option. It explains part of why stress resilience varies between individuals, why PTSD involves measurable neurochemical changes, and why the stress response is not simply a matter of willpower. The peptide itself is not commercially available in a form that would allow self-experimentation, and there is no established protocol for therapeutic use outside of research settings.
Verdict Recapitulation
Evidence Tier 2 — Clinical Trials. Phase Ib data exists from an intranasal PTSD trial and a small MDD RCT. Both showed signals; neither led to a drug.
Verdict: Eyes Open. The biology is strong, the clinical evidence is early, and the delivery problem is real. NPY teaches us something important about stress resilience at the molecular level—but teaching us something and treating a disease are different things.
For readers considering Neuropeptide Y, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Neuropeptide Y
Further Reading and Resources
If you want to go deeper on Neuropeptide Y, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Neuropeptide Y — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sayed S, et al. Intranasal neuropeptide Y (NPY) for treatment of PTSD: a randomized, double-blind, placebo-controlled, Phase Ib dose-ranging study. Int J Neuropsychopharmacol. 2018;21(1):3–11 PubMed
- Mathé AA, et al. Intranasal neuropeptide Y in major depressive disorder: a randomized, double-blind, placebo-controlled trial PubMed
- Sah R, et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry. 2009;66(7):705–707 PubMed
- Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38(4):213–224 PubMed
- Morgan CA III, et al. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry. 2002;52(2):136–142 PubMed
- Tatemoto K, et al. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296(5858):659–660 PubMed
- de Lecea L, et al. Cortistatin is expressed in a distinct subset of cortical interneurons. J Neurosci. 1997;17(15):5868–5880 PubMed
- Rasmusson AM, et al. A decrease in cerebrospinal fluid neuropeptide Y precedes increased symptom severity in posttraumatic stress disorder. Biol Psychiatry. 2010;68(3):286–293 PubMed
DISCLAIMER
Neuropeptide Y is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.